Commodore Capital LP Discloses 7.7% Stake in Enliven Therapeutics, Inc. (ELVN)

Commodore Capital LP, along with Commodore Capital Master LP and managing partners Michael Kramarz and Robert Egen Atkinson, filed a Schedule 13G/A on May 15, 2026, disclosing a significant position in Enliven Therapeutics, Inc. (ELVN). As of March 31, 2026, the reporting group beneficially owns 4,800,940 shares of Common Stock, representing a 7.7% ownership stake in the company. This holding consists of 3,275,000 shares of Common Stock and 1,525,940 shares underlying pre-funded warrants. The pre-funded warrants are subject to a beneficial ownership limitation of 9.99%. The filing indicates an increase from zero reported shares in previous snapshots, establishing Commodore Capital as a major institutional investor in the clinical-stage precision oncology company. The investment is managed by Commodore Capital LP, with Kramarz and Atkinson exercising investment discretion. The filing was made under Rule 13d-1(c), certifying that the shares were not acquired for the purpose of changing or influencing the control of the issuer.